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Abstract
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INTRODUCTION—Findings for genetic correlates of late onset Alzheimer’s disease (LOAD) in
studies that rely solely on clinic visits may differ from those with capacity to follow participants
unable to attend clinic visits.
METHODS—We evaluated previously-identified LOAD-risk single nucleotide variants in the
prospective Adult Changes in Thought study, comparing hazard ratios (HRs) estimated using the
full data set of both in-home and clinic visits (n=1697) to HRs estimated using only data that was
obtained from clinic visits (n=1308). Models were adjusted for age, sex, principal components to
account for ancestry, and additional health indicators.
RESULTS—LOAD associations nominally differed for 4 of 21 variants; CR1 and APOE variants
were significant after Bonferroni correction.
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DISCUSSION—Estimates of genetic associations may differ for studies limited to clinic-only
designs. Home visit capacity should be explored as a possible source of heterogeneity and
potential bias in genetic studies.
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1. Introduction1
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Study design is underemphasized in planning or interpretation of many genome-wide
association studies (GWAS) and sequencing projects [1]. In many settings, issues such as
sampling, recruitment and data collection strategies are assumed to be of secondary
importance, although the potential for bias is well-established. Many GWAS analysis
projects amass participants from cohorts with varying recruitment strategies and
phenotyping protocols. In resulting manuscripts, these details are often relegated to
supplementary information or not described at all.
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Even subtle differences in subject ascertainment between studies could produce result
heterogeneity, and such heterogeneity may be due to true differences in the relevance of
genetic variants across subgroups or due to bias induced by selection processes. Many
GWAS statistical models include few covariates, so subgroup effect heterogeneity is not
explored and there is little hope of correcting selection bias. If gene-environment
interactions exist, or if the genetic effect occurs only in a subgroup of people, success of the
GWAS framework may be especially dependent on the sample selection process as it affects
the distributions of potentially important subject characteristics. More troubling, if genetic
variants and symptoms of incipient AD interact in determining chances of participating in
genetic studies, the observed association between the genetic variant and AD may be
severely biased when estimated in the participants. Indeed, such a process can create an
observed association that does not match the true effect even among study participants. Of
course, most studies cannot evaluate this possibility because they have no information on
study non-participants. Not accounting for these scenarios can result in bias and/or diluted
statistical power [2–6].
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We recently published findings from a prospective cohort with a two-stage sample design
indicating that genetic associations with LOAD for the APOE locus may differ for
individuals who attend in-person clinic visits than for the larger community-dwelling
population, which includes some people who do not attend study visits in a research
clinic[7]. We determined that risk factor associations with LOAD differed for participants
who had only in-clinic visits versus the full sample that also included people seen at home.
For APOE ε4 the estimated hazard ratio for incident LOAD in the full sample was 1.66
(95% confidence interval [CI] 1.37, 2.01), while in the clinic only dataset, APOE ε4 had a
hazard ratio of 2.28 (95% CI 1.57, 3.30). The p-value for this difference was 0.008. APOE
was the only genetic factor we evaluated.

1Abbreviations: ACT: Adult Changes in Thought. AD: Alzheimer’s disease. CI: Confidence interval. HR: Hazard ratio. LOAD: Lateonset AD.
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The notion that study design could be important in the relevance and magnitude of
associations with APOE has been known previously[8]. Indeed, while APOE genotype may
be strongly predictive of LOAD status in specialty clinic settings, this association is
attenuated in community-based settings[9]. We hypothesized that this pattern could be
explained by selection bias due to specialty clinic studies lacking home study visit capacity.
This phenomenon may also apply to other genetic variants. It is important to distinguish
between the consequences of bias (e.g., estimated effects that are not, on average, centered
about the true value and diminished power (i.e., less chance of discovering a true effect).
We used genetic and research study data from the Adult Changes in Thought (ACT) study to
determine whether home study visit capacity would have an influence on the strengths of
association with LOAD found in ACT with LOAD SNVs from the largest LOAD GWAS
meta-analysis to date[10].
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2. Methods
2.1. Parent study description, ethical considerations, and funding
Methods for ACT have been published[11–13]. The original cohort enrolled 1994–1996
included 2,581 randomly selected dementia-free people age ≥65 who were members of
Group Health, a Washington State health care system. An additional 811 participants were
enrolled 2000–2003, and in 2005 we began continuous enrollment. Participants are
evaluated at 2-year intervals at a research clinic or in their home at the participant’s choice.
Other than location (i.e., home vs. clinic), screening research study visits are identical.
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Study procedures were approved by Institutional Review Boards of Group Health and the
University of Washington. Participants provided written informed consent. ACT is supported
by the National Institute on Aging, which had no role in study design; in the collection,
analysis, and interpretation of data; in the writing of the report; or in the decision to submit
the paper for publication.
2.2. LOAD identification

Author Manuscript

Participants were assessed at home or in clinic every 2 years with the Cognitive Abilities
Screening Instrument (CASI), for which scores range from 0 to 100 and higher scores
indicate better cognitive functioning[14]. Participants with scores of 85 or less underwent
further evaluations, including a clinical examination and a battery of neuropsychological
tests; dementia evaluations are in the participant’s home regardless of the location of the
triggering/screening visit. Results of these evaluations, laboratory testing, and imaging
records were reviewed in a consensus conference, where research criteria were used to
identify cases of dementia[15] and probable or possible AD[16]. Dementia-free participants
continued with scheduled follow-up visits. In this study, we are examining whether
associations between genetic variants and LOAD differ for people who participated in
biennial screening visits in the clinic compared to all study participants; by design in ACT,
the dementia evaluations all occur in the participant’s home, so the location of these
evaluations is not under study here.
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2.3. Genotyping
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ACT participants were genotyped in two waves. The bulk of the cohort was genotyped using
the Illumina Human 660 Quad chip, and a subsequent genotyping wave used the Illumina
OmniExpress chip. Data from European Americans from both samples were imputed to the
same CEU Human HapMap reference panels as used in the International Genomics of
Alzheimer’s Project (IGAP) paper from Lambert et al[10]. APOE genotype was obtained
separately using standard procedures. Of the other 21 SNVs identified as the top hits in
Lambert et al.[10], 20 were available in the ACT data either being directly genotyped or
successfully imputed; the lone exception was the DSG2 SNV.
2.4. Statistical analyses

Author Manuscript
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We limited our analyses to European Americans based on principal components analysis (a
conventional statistical genetics approach to discern ancestry from GWAS data[17]) as well
as self-reported white race. We constructed two datasets from the subset of the ACT study
with at least one follow-up visit and full genotype data (~1/3 of ACT participants): a
complete data set including information for all participants and all visits (the “all visits”
dataset), and a second set that mirrored what a clinic based study would have achieved by
excluding people who never attended a clinic visit (the “clinic only” dataset). By definition,
participants whose entire set of visits consisted of home visits are not included in the “clinic
only” dataset. The “all visits” dataset comprises 1697 individuals with a total of 7997
follow-up visits, 15,972 person-years of time in the ACT study, and 419 cases of incident
dementia or LOAD resulting in an incidence rate of 26.2 cases per person-year. The “clinic
only” dataset includes 1308 individuals with a total of 5106 follow-up visits, 10,350 personyears, and 96 cases of incident dementia or LOAD corresponding to an incidence rate of 9.3
cases per person-year.
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We modeled probable or possible AD as the dependent outcome[16]. Because the ACT
study is a prospective cohort study and all cases were incident cases of LOAD, we used Cox
proportional hazards regression models with age as the time axis[18] and included age at
baseline, sex, and three principal components as covariates. For our primary analyses, we
also included years of formal schooling as well as self-reports from baseline of diabetes,
hypertension, coronary heart disease (a composite including self-reported heart attacks,
angina, coronary artery bypass grafting, or angioplasty), cerebrovascular disease (a
composite including stroke, transient ischemic attack, or carotid surgery), and quartiles of
medical comorbidity as estimated with the prescription-medications-based RxRisk
measure[19]. The assumption of proportional hazards was tenable for all models. We also
evaluated logistic regression models including only sex, age at baseline, and three principal
components to facilitate a more direct comparison with the Lambert et al. analyses[10]. Our
primary analyses with multiple covariates are analogous to epidemiological investigation of
candidate risk factors, while our sensitivity analyses are analogous to standard genome-wide
discovery analyses in GWASs.
We compared hazard ratios from the “all visits” and “clinic only” datasets using a
bootstrapping procedure to evaluate whether differences were plausibly due to sampling
variability (i.e., chance). We drew (with replacement) random subsets from the “all visits”
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dataset that were the same size as the “clinic only” dataset. Each randomly drawn resample
has the same size as the “clinic only” dataset, allowing us to evaluate how often, if the
“clinic only” dataset was a random sample of the full data set, we would see associations as
extreme or more than we observed in the actual “clinic only” dataset. In each resampled
“clinic only” dataset, we performed the same adjusted analyses of the association between
the SNV and LOAD risk. We determined the proportion of resampled “clinic only” datasets
with hazard ratios more extreme than those from the actual “clinic only” dataset. The
bootstrap p-values indicate the proportion of drawn datasets with more extreme findings than
the actual “clinic only” dataset, which help us understand whether “clinic only” and “all
visits” hazard ratios differ more than expected by chance alone. We compared the absolute
values of effect sizes in the actual “clinic only” data set to the resampled datasets so we have
a 2-sided p-value. The bootstrapped p-values represent the evidence of incompatibility with
the given statistical model that includes the assumption that the “clinic only” dataset is a
random sample from the “all visits” dataset. Thus, they provide a test of whether the
differences between the HRs estimated in the “clinic only” and “all visits” datasets could
plausibly be due to chance. We consider both nominal (p<0.05) and Bonferroni corrected
(p<0.05/21) thresholds.
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We used Stata 14.1 (StataCorp, College Station, TX) for all analyses.

3. Results
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Demographic and clinical data from the LOAD cases and controls are shown in Tables 1 and
2. These data comprise the “all visits” dataset. There were many distinct patterns of home
and clinic visits over time for ACT participants. The distribution of pattern types is
presented in Table 2. For the “clinic only” dataset, we excluded all home visit data. This
means the 163 people with no clinic visits were excluded. In addition, 389 participants with
fewer than two clinic visits were excluded because they had no clinic follow-up to contribute
to survival time. In addition, we excluded the home visits (but kept the clinic visits) for 913
participants with a mix of home and clinic visits, usually resulting in shorter follow-up time
and sometimes missing a dementia diagnosis triggered by a home visit for those study
participants. Minor allele frequencies for variants in genes other than APOE are in
Supplementary Table 1.
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In the “all visits” dataset, we observed significant associations with LOAD hazard for SNVs
in CR1 (rs6656401, p=0.007), CD2AP (rs10948363, p=0.006), PTK2B (rs28834970,
p=0.009), CD33 (rs3865444, p=0.026), ABCA7 (rs4147929, p=0.023), and APOE
(p<0.0001) (see Table 3). Hazard ratios quantify different measures of risk than odds ratios.
Nevertheless, the corresponding HR estimates are of similar magnitude and in the same
direction as the OR estimates from Lambert et al.[10] (Table 3 and Supplementary Table).
For only two of these loci – CR1 and APOE – were results significant in the “clinic only”
dataset (both p-values <0.0001); no other loci had significant associations with LOAD
hazard for the “clinic only” sample.
We next evaluated whether differences in estimates from the “clinic only” dataset and the
“all visits” dataset were larger than expected by chance alone. Four of the 21 investigated

Alzheimers Dement. Author manuscript; available in PMC 2018 August 01.

Fardo et al.

Page 6

Author Manuscript

SNVs had nominally significant bootstrap p-values; the difference between the HR in the
clinic only data set and the HR in the all visit data set was unlikely to have emerged by
chance due to sampling variability. In decreasing order of significance, we observed
nominally significant results for APOE (p<0.0001), CR1 (rs6656401, p=0.0001), CD33
(rs3865444, p=0.007), and EPHA1 (rs11771145, p=0.014). Three of these – APOE, CR1,
and CD33 – were associated with significant LOAD hazard in the “all visits” dataset. When
employing logistic regression to calculate effect estimates, odds ratios differed significantly
between the clinic only and all visit data sets for these same three variants, plus the
PICALM SNV (rs10792832, p=0.014) (Supplementary Table 2). After Bonferroni
adjustment for testing each of 21 SNVs, the results from APOE and CR1 remained
significant.
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The APOE ε4 allele was associated with higher risk of LOAD, with hazard ratio (HR) for
the “all visits” dataset of 1.92 (95% CI 1.60, 2.32). As in our previous publication, the
strength of this association was much higher for the “clinic only” dataset, with a HR of 3.26
(95% CI 2.30, 4.63). These estimates were more divergent than likely to occur by chance
alone (bootstrapping p<0.0001). Similar to APOE, results for CR1 on chromosome 1
(rs6656401) were much stronger in the “clinic only” dataset, with HR 2.13 (95% CI 1.49,
3.05), than the “all visits” dataset (HR 1.29, 95% CI 1.07, 1.55). Bootstrapping again
confirmed that these estimates were much more distinct than expected by chance alone
(bootstrapping p=0.0001; Figure 1).
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Results for CD33 on chromosome 19 (rs3865444) from the “all visits” dataset (HR 0.84,
95% CI 0.71, 0.98) were similar to those observed in Lambert et al. (odds ratio=0.94, 95%
CI 0.91, 0.96)[10]. Results for the “clinic only” dataset were in the opposite direction
(HR=1.12, 95% CI 0.81, 1.55), though the confidence interval was broad. Bootstrapping
results for rs3865444 were nominally significant (bootstrapping p = 0.007). Results for
rs11771145 associated with EPHA1 on chromosome 7 were essentially null for the “all
visits” dataset (HR=1.02), and the confidence interval included the odds ratio estimate from
Lambert et al. (OR = 0.90 95% CI 0.88, 1.18[10]). The result for the “clinic only” dataset
(HR=0.83) was stronger than that seen in Lambert et al., though the confidence interval was
wide and included both the point estimate from the “all visits” dataset and that reported by
Lambert et al. (OR = 0.90 95% CI 0.62, 1.13). Bootstrapping results for rs11771145
suggested this difference was nominally significant (bootstrap p = 0.014).
For all loci, results from models that included adjustment only for age, sex, and three
principal components were similar (not shown).
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4. Discussion
The ACT study enables each participant to choose whether they would like to have each
study visit at a central research clinic or at their own home. As participants age, higher
proportions of participants opt for home study visits[7]. In particular, as many participants
progress to dementia, their ability or willingness to navigate the world to attend a research
clinic visit is dramatically attenuated, as indicated by the fact that of the 419 people with
incident LOAD in this report, only 96 had their AD diagnosed following an in-clinic study
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screening visit; the remaining 319 people (76%) had their LOAD diagnosed following an inhome study screening visit. By design, all detailed dementia diagnosis evaluations occur at
participant homes; we focused here on the location of the screening visits that were either in
our research clinic or in the participant home. Because the ACT study includes capacity for
home study screening visits, we are able to address the question of whether associations
from all ACT study screening visits are different from associations observed among the
subset of study screening visits at our research clinic. We previously demonstrated large
differences for risk factors for LOAD and for associations between neuropathology findings
at autopsy and dementia status during life[7].

Author Manuscript
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Here we performed similar analyses but considered associations with SNVs previously
found to be associated with LOAD risk[10]. The “clinic only” dataset was smaller than the
all-visit cohort in terms of the number of people (n=1308 vs. n=1697), follow-up time
(around 10,000 person-years vs. nearly 16,000 person-years), and number of incident LOAD
cases (96 vs. 419). It was thus not a surprise that more loci were nominally statistically
significantly associated with LOAD risk in the “all visits” dataset. As in our previous
publication, we found large differences between the “clinic only” dataset and the “all visits”
dataset for APOE genotype. APOE ε4 alleles were associated with increased risk for LOAD
in the “all visits” dataset, with a HR of 1.92, but they were much more strongly associated in
the “clinic only” dataset, with a HR of 3.26. We used bootstrapping to determine the
statistical significance of this difference, and found this difference in risk estimates to be
very unlikely to be due to chance alone (bootstrapping p<0.0001). This provides strong
evidence against chance being responsible for differences, which leads to a conclusion that
the assumptions underlying the model (e.g., no selection bias and no confounding) likely do
not hold. We similarly found large differences for rs6656401 associated with CR1, where the
HR estimate was much smaller for the “all visits” dataset (1.29) than the “clinic only”
dataset (2.13) (bootstrapping p <0.0001). We found a smaller difference for rs3865444
associated with CD33, however the estimates were in opposite directions, such that the “all
visits” estimate was consistent with the previously published association from Lambert et al.
(“all visits” HR=0.84; “clinic only” HR=1.12; bootstrapping p = 0.007).
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Thus, with “clinic only” data, we know that the results may be different than what we would
observe with a more complete dataset that more closely resembles the underlying
population, but we do not know in which direction to expect any differences. Taken together
with our prior investigations[7] and viewed as a missing data problem, these results provide
further evidence that data missing due to the lack of home study visit capacity are missing
not at random (MNAR). This conclusion has important implications. Results from studies
with outcomes that are MNAR may be biased – they provide the wrong answer – and we do
not know the direction of the possible bias. It is not difficult to envision a scenario such that
the act of opting for a home visit relays important information regarding LOAD risk and the
subsequent statistical models needed to estimate causal effects.
When data are MNAR, deriving unbiased effect estimates relies on incorporating corrections
for the missingness mechanism (i.e., what causes people to select out of clinic-based
studies). Since the missingness mechanism is almost never known, this relies on sensitivity
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analyses exploring a range of possible missingness mechanisms [20]. Our results can help
guide such sensitivity analyses in data sets that include only clinic-based data.
We chose to focus only on SNVs previously identified to be associated with LOAD risk.
Most of these SNVs have been replicated in multiple waves of sampling, though rs3865444
associated with CD33 was essentially null in the second stage of the Lambert et al.
study[10]. Since the Lambert et al. paper includes data from many studies with many study
designs, some of which include and others of which do not include home study visit
capacity, there may well be additional SNVs that would be discovered if all of the data were
from studies that include home visit capacity, but that are not identified with genome-wide
significance levels at present. There is additional expense associated with following older
study participants at home. Our results strongly support the value of this expenditure in
terms of the validity of genetic findings.
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A similar point can be made in a much broader context outside of home visit capacity and
even Alzheimer’s disease research. That is, there are study design factors that may appear so
subtle as to not warrant mention in analysis manuscripts, but that can nevertheless affect
interpretation and both internal and external validity of results. Finding and addressing these
areas of heterogeneity could lead to discovery of novel disease variants. Heid et al.[1]
conducted meta analyses for a SNV found to correlate with BMI and concluded that
association estimates depended on the design; specifically, whether subjects were recruited
from a general population or a healthy population. In the case of AD, our investigations
strongly suggest that whether studies have home study visit capacity can likewise have a
critical impact on genetic findings of associations with LOAD risk. We suspect there may be
other apparently subtle design factors that may lead to important heterogeneity across
studies and that may interfere with our ability to identify associations with LOAD. We could
speculate that there may be important differences between people who opt for in-home visits
and people willing to attend a research clinic visit, and that these differences may be related
to genetic factors and predisposition to LOAD. This is consistent with the results that some
SNV effects appear more extreme in the “clinic only” sample due to the induced bias while
others are only significant when using all data possibly solely due to increased sample size.
An important question is whether the effect estimates in the clinic only sample are correct
for those individuals, or biased even for that subsample. In other words, are the differences
we observe due to true effect heterogeneity or due to a bias from the selection process?
Either explanation is consistent with our statistical findings.
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Our findings should be considered in the context of limitations. There is some attrition in the
ACT study despite including capacity for home visits. Our completeness of follow-up
index[21] is exemplary but not perfect. It is not known whether similar healthy participant
bias may influence the results that we observe. We doubt that would be the case due to the
overall low rates of study attrition, but cannot rule out that possibility. Unmeasured and
residual confounding are always possibilities in observational studies, though our findings
were essentially the same with sparser “genetic style” analyses as with covariate-rich
“epidemiology style” analyses. Underrepresented ethnic diversity of the ACT study is
somewhat restricted, though the demographic makeup of our study cohort reflects that of
King County. As in the Lambert et al. paper the analyses presented here were limited to
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people of European ancestry. Home visit capacity has been specifically advocated as a
means of increasing underrepresented ethnic participation in dementia studies[22].
Our findings support the importance of home visit data collection capacity in the design of
genetic studies of LOAD risk. Studies that only include research clinic study visit data
collection may lead to biased conclusions. These results suggest that new LOAD genetics
studies at the design stage should consider incorporating home visit data collection capacity
despite its expense and administrative complexity. Existing studies should routinely report
on this important detail of study design in reports of study findings. Studies that lack home
study visit capacity should specify that as a possible limitation, and should be cautious in
interpreting study findings. Similarly, meta-analyses of LOAD genetic analyses should
consider whether home study visit capacity may be a source of between-study heterogeneity.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in Context (149 words)
Systematic review
Relevant literature was reviewed using Google Scholar and PubMed. Publications that
address possible bias in genetic association studies and studies without home visit
capacity were cited. None address the validity of genome-wide association study results
in the context of home visit capacity.
Interpretation

Author Manuscript

Our results suggest that the capacity for home research study visits is an important factor
in the design of genetic studies of Alzheimer’s disease and dementia. This observation
implies that there are likely important design differences in genetic studies across
research areas. When studies are aggregated via meta analysis or otherwise, any inference
must be carefully interpreted.
Future directions
This paper indicates that home research visit capacity should be considered at the design
stage of genetic association studies. Other genetic studies of Alzheimer’s disease,
dementia and other disorders can result in bias due to study design differences when
aggregating information across potentially disparate cohorts.
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Figure 1.
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Empirical distribution of the beta coefficient for the association between rs6656401 and risk
of Alzheimer’s disease. We sampled with replacement from the “all visits” data set a sample
of people the same size as the “clinic only” data set and performed Cox regression on that
data set of the association between the risk factor and risk of Alzheimer’s disease. We
captured the beta coefficients from those models; exponentiated beta coefficients from these
models are hazard ratios. We repeated this procedure 10,000 times. The vertical line at 0.26
was the result we obtained with the entire “all visits” data set; this value is the natural
logarithm of the estimated hazard ratio (1.29). The vertical line at 0.70 was the result we
obtained with the “clinic only” data set; that value is the natural logarithm of the estimated
hazard ratio (2.01). The graph shows that the bootstrapping results are normally distributed
with a central tendency very close to the observed value from the entire “all visits” data set;
the observed result from the “clinic only” data set is far from that value, and none of the
10,000 sampled data sets had values that extreme. These 10,000 beta coefficients were used
to arrive at the p-value of 0.0001 shown in Table 3
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Demographic and clinical characteristics (n=1697).
Characteristic

N or mean

% or SD

Male sex

719

42 %

Age

74.9

6.3

≤12 years

533

31%

13–16 years

740

44%

≥17 years

424

25%

Education

Author Manuscript

Diabetes at baseline

139

8%

Hypertension at baseline

642

38%

Heart disease at baseline

305

18%

Cerebrovascular disease at baseline

154

9%

First quartile

612

36%

Second quartile

362

21%

Third quartile

396

23%

Fourth quartile

322

19%

2/2

8

<1%

2/3

210

12%

2/4

31

2%

3/3

1039

62%

3/4

373

22%

4/4

24

1%

2

170

10%

3

239

14%

4

223

13%

5

279

16%

6

169

10%

7

227

13%

* RxRisk score at baseline

APOE genotype
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Number of visits completed

8–11

390

23%

Total visits

5.7

2.6

Home visits

1.7

1.9

Study cohort
Original (1994–1996)

Author Manuscript

1134

67%

Expansion (2000–2003)

379

22%

Continuous (2005-)

184

11%

*

Higher RxRisk scores represent greater comorbidity[19]
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Distribution of visit patterns
Pattern

N (%)

All visits occurred at the clinic

621 (37%)

One or more clinic visits followed by one or more home visits

845 (50%)

One or more clinic visits followed by one or more home visits and at least one more clinic visit

34 (2%)

One or more home visits followed by one or more clinic visits

11 (1%)

One or more home visits followed by one or more of clinic visits and at least one more home visit
All visits occurred at home

23 (1%)
163 (10%)
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0.99 (0.56, 1.71)

3.26 (2.30, 4.63)

1.19 (0.82, 1.73)

1.12 (0.81, 1.55)

1.33 (0.82, 2.17)

1.08 (0.76, 1.54)

0.96 (0.70, 1.31)

1.07 (0.53, 2.16)

0.99 (0.72, 1.36)

0.82 (0.60, 1.12)

1.25 (0.82, 1.91)

1.17 (0.85, 1.61)

0.88 (0.64, 1.29)

0.95 (0.68, 1.33)

0.83 (0.61, 1.13)

1.08 (0.75, 1.54)

1.11 (0.79, 1.55)

0.84 (0.60, 1.17)

1.19 (0.85, 1.66)

0.90 (0.67, 1.21)

2.13 (1.49, 3.05)

HR

Clinic only

0.940

<0.0001

0.361

0.490

0.254

0.679

0.794

0.853

0.959

0.212

0.300

0.326

0.411

0.769

0.230

0.682

0.553

0.296

0.317

0.491

<0.0001

p-value

0.772

0.0001

0.885

0.007

0.168

0.063

0.478

0.565

0.834

0.145

0.264

0.466

0.626

0.445

0.014

0.281

0.250

0.999

0.614

0.515

<0.0001

p-value

The hazard ratios (HRs), 95% confidence intervals and p-values in the All visits (Clinic only) columns are derived from testing each SNV in a Cox proportional hazards model using the All visits (Clinic
only) dataset and adjusting for age at baseline, sex, the first three principal components (PCs), years of formal schooling, indicators of self-reported diabetes, hypertension, coronary heart disease and
cerebrovascular disease and quartiles of the RxRisk measure. Models adjusting solely for age at baseline, sex and the first three PCs were similar (not shown). The 2-sided bootstrap p-values are equal to the
proportion of the 10,000 bootstrap “clinic only” replicates that result in an estimated hazard ratio more extreme than that from the actual “clinic only” data employing the same Cox proportional hazards
model.

0.770

<0.001

0.023

0.026

0.530

0.135

0.167

0.911

0.632

0.301

0.491

0.009

0.273

0.779

0.799

0.633

0.006

0.187

0.146

0.688

0.007

p-value

APOE was genotyped separately and modeled using counts of the ε4 allele.

*

0.96 (0.74, 1.25)

CASS4

1.22 (1.03, 1.46)

rs7274581

0.84 (0.71, 0.98)

CD33

20

1.08 (0.85, 1.37)

FERMT2

1.92 (1.60, 2.32)

0.88 (0.74, 1.04)

APOE

0.90 (0.78, 1.04)

MS4A6A
SLC24A4-RIN3

ABCA7

0.98 (0.68, 1.41)

n/a*

0.96 (0.82, 1.12)

CELF1
SORL1

rs4147929

0.93 (0.80, 1.07)

19

1.07 (0.89, 1.29)

CLU
PICALM

19

1.21 (1.05, 1.40)

rs3865444

0.92 (0.80, 1.07)

NME8
PTK2B

rs17125944

1.02 (0.87, 1.20)

19

1.02 (0.88, 1.18)

EPHA1
ZCWPW1

14

0.96 (0.81, 1.13)

rs983392

1.24 (1.06, 1.44)

CD2AP
HLA-DRB5-HLA-DRB1

rs10498633

0.90 (0.76, 1.05)

14

1.13 (0.96, 1.33)

0.97 (0.84, 1.12)

BIN1

1.29 (1.07, 1.55)

CR1
INPP5D

MEF2C

HR

Gene

11

rs11218343

8

rs10838725

rs2718058

rs28834970

7

11

rs1476679

7

11

rs11771145

7

rs9331896

rs9271192

6

rs10792832

rs10948363

6

8

rs190982

11

rs6733839

2

5

rs6656401

rs353349669

1

2

SNV

CHR

All visits
Bootstrap result
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SNV findings from the “all visits” dataset, and from the “clinic only” dataset
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